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ABSTRACT: We have realized the direct ionization of
samples from wells of microtiter plates under atmospheric
conditions for mass spectrometry analysis without any liquid
delivery system or any additional interface. The microtiter plate
is a commercially available 384-well plate without any
modiﬁcation, working as a container and an emitter for
electrostatic spray ionization of analytes. The approach
provides high throughput for the large batches of reactions
and both the qualitative and quantitative analysis of a single
compound or mixture. The limits of detection in small drug
molecules, peptides, and proteins are similar in comparison
with standard direct infusion electrospray ionization. The
analysis time per well is only seconds. These analytical merits
beneﬁt many microtiter plate-based studies, such as combinatorial chemistry and high throughput screening in enzyme assay or
drug metabolism. Herein, we illustrate the application in enzyme assay using tyrosine oxidation catalyzed by tyrosinase in the
presence or absence of inhibitors. The potential application in drug development is also demonstrated with cytochrome P450-
catalyzed metabolic reactions of two drugs in microtiter plates followed with direct ESTASI-MS/MS-based characterization of
the metabolism products.
Microtiter plates are used as a standard tool in analyticalchemistry, clinical assay, and life science study. Because
of the large number of wells per plate, it is widely used for
combinatorial chemistry and high throughput screening.
Coupled with various chemical analysis techniques, such as
ultraviolet−visible spectroscopy, ﬂuorescence spectroscopy,
liquid chromatography (LC), capillary electrophoresis (CE),
and mass spectrometry (MS), it is extensively used for enzyme-
linked immunosorbent assays (ELISA),1 enzyme activity or
inhibition assays,2,3 and drug metabolism studies.4,5 Compared
to spectroscopy techniques, MS can oﬀer direct qualiﬁcation
and quantiﬁcation of a wide range of analytes, providing
accurate and speciﬁc characterization to avoid false positive or
negative results, and thereby is highly suitable for the studies of
enzymatic assays, inhibitor screening assays, and drug
metabolism assays.6−10
MS is normally coupled with microtiter plates with the help
of liquid delivery robots. For instance, Advion has commer-
cialized a TriVersa NanoMate system, which collects fractions
during LC-MS in a 96- or 384-well plate, that are later analyzed
by electrospray ionization (ESI) MS via an ESI chip. This
system has been used in lipidomic studies, screening of drug
metabolism, protein−ligand interaction study, biotherapeutics,
etc.11−14 In a more common way, autosamplers from various
suppliers are used in coupling microtiter plates with MS.
However, the use of autosamplers limits the throughput of
analyses, especially in comparison with spectroscopy-based
microtiter plate assays. There have been a lot of eﬀorts spent to
modify autosamplers to overcome the disadvantage. A
multiprobe autosampler was developed by Kassel et al. to
couple with ﬂow injection MS, where the analysis of a whole
96-well plate could be ﬁnished in 12 min instead of 48 min by a
single-probe autosampler.15 Later on, it was further optimized
by Morand et al. to ﬁnish the analysis of a 96-well plate in 5
min.16 Another option is avoiding using autosamplers all
together, but with a ESI interface for direct infusion and
ionization of samples from a microtiter plate for MS
analysis.17,18 Recently, Trimpin et al. have presented direct
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ionization from a 96-well plate by a solvent assisted ionization
inlet (SAII), where disposable micropipette tips were modiﬁed
on each well of the 96-well plate to form an ionization device
with the original wells as containers and the pipet tips as
emitters.19
Herein, we have realized direct ionization of liquid samples
from an unmodiﬁed microtiter plate, where the plate itself
works as both containers and emitters for ionization. To the
best of the authors’ knowledge, it is the ﬁrst method of direct
ionization from a microtiter plate without any liquid delivery
interface and any modiﬁcation to the plate. The ionization is
achieved using the recently developed electrostatic spray
ionization (ESTASI).20−22 The microtiter plate is simply placed
between the ion transfer capillary of a mass spectrometer and
the electrode connected to a pulsed high voltage (HV) power
source. When the pulsed HV is applied, ESTASI occurs to
generate alternative spray of cations and anions for MS
analysis.20
The performance of the ionization for qualiﬁcation and
quantiﬁcation was evaluated. Diﬀerent types of samples,
including small drug molecules, amino acids, peptides, and
proteins could be detected with limits of detection (LOD)
similar to those of standard direct infusion ESI. Quantitative
analysis was also realized by adding a proper internal standard
into the tested sample. Because the microtiter plate is
disposable and no liquid delivery is needed, washing steps
can be avoided to shorten analysis time and eliminate cross-
contamination between samples. The analysis time per well is
only few seconds to generate a mass spectrum. With these
advantages, the technique is highly suitable for fast analysis of a
single compound or mixture. In addition, it holds potential
applications in high throughput assays, such as enzyme
inhibition screening and drug metabolism studies. To illustrate
these, tyrosinase-catalyzed oxidation of tyrosine with or without
inhibitors and in vitro drug metabolism by cytochrome P450 in
microtiter plates were directly read by ESTASI-MS.
■ EXPERIMENTAL SECTION
Chemicals and Materials. Ciproﬂoxacin (CIP), enroﬂox-
acin (ENR), lomeﬂoxacin (LOM), and ﬂeroxacin (FLE) of
analytical reagent grade were purchased from TCI Deutschland
GmbH (Eschborn, Germany). Angiotensin I (Ang I, 98%) was
obtained from Bachem (Bubendorf, Switzerland). Cytochrome
c (Cyt c, horse heart, 95%), magnesium chloride hexahydrate
(98%), sodium phosphate dibasic dodecahydrate (99%),
sodium phosphate monobasic (99%), and sodium chloride
(99.5%) were obtained from Fluka (St. Gallen, Switzerland).
Methanol (99.9%, HPLC grade) was purchased from
Applichem GmbH (Darmstadt, Germany). Acetic acid (HAc,
99%) was obtained from Merck (Zug, Switzerland). Ammo-
nium bicarbonate (NH4HCO3, 99%,), calcium chloride (93%),
tyrosinase (from mushroom, lyophilized powder, ≥1000 unit/
mg solid), L-tyrosine (99%), reduced nicotinamide adenine
dinucleotide phosphate (NADPH), nifedipine (≥98%, pow-
der), testosterone (≥98%, powder), and cytochrome P450
CYP3A4 isozyme microsomes expressed in baculovirus-infected
cells were purchased from Sigma-Aldrich (St. Gallen, Switzer-
land). Potassium chloride (99%) was obtained from Roth AG
(Arlesheim, Switzerland). Cupferron (for analysis) was
purchased from Fisher Scientiﬁc (Waltham, MA, USA). All
these reagents and materials were used as received without
further puriﬁcation. Deionized water (18.2 MΩ cm) was
obtained from an ultrapure water system (Milli-Q 185 Plus,
Millipore) and used for all experiments. A MicroAmp optical
384-well reaction plate with a barcode was purchased from life
technologies (Carlsbad, CA, USA).
Tyrosine Oxidation and Drug Metabolism. Wells of a
384-well microtiter plate were ﬁlled with 8 μL of phosphate
buﬀered saline (PBS, 2 mM, pH 7.4), 1 μL of tyrosinase (0.2
mg/mL in 2 mM PBS), and 1 μL of tyrosine (0.5 mg/mL in 2
mM PBS). The detection by ESTASI-MS was directly
performed from the wells at diﬀerent time intervals to monitor
the oxidation results. When enzyme inhibition was studied, 1
μL of ascorbic acid (AA, 1 or 0.1 mg/mL in 2 mM PBS), or 1
μL of Cupferron (20 mM in 2 mM PBS) was added, followed
by the addition of 7 μL of PBS (2 mM), 1 μL of tyrosinase (0.2
mg/mL in 2 mM PBS), and 1 μL of tyrosine (0.5 mg/mL in 2
mM PBS).
For drug metabolism, 80 μg/mL of nifedipine or 40 μg/mL
of testosterone was prepared in 10 mM NH4HCO3 (pH 7.4),
respectively. NADPH (1 μL of 50 mg/mL in 10 mM
NH4HCO3), 1 μL of CYP3A4 (1 μM in 100 mM KH2PO4,
pH 7.4), and 8 μL of the drug solution were added in multiple
wells of a 38-well plate. After being incubated for diﬀerent
periods at room temperature, 9 μL of the reaction solution was
discarded and 9 μL of 50% MeOH/49% H2O/1% acetic acid
was added for ESTASI-MS analysis.
ESTASI-MS. ESTASI-MS was performed as described in
previous publications20,23 and illustrated by Figure 1. A 384-
well plate was placed on a PET substrate (120 μm thickness),
and all together between an electrode and the ion transfer
capillary of a linear ion trap mass spectrometer (LTQ Velos,
Thermo scientiﬁc). The ion transfer capillary was a self-
designed “L-shaped” ion transfer capillary instead of the original
linear one of the MS instrument, which could maintain a
Convectron Gauge value of 1 Torr for good ion transfer into
the mass spectrometer. The modiﬁcation was carried out in
order to place the microtiter plate horizontally for MS analysis.
The plate was moved in x, y, and z directions by travel
translation stages to bring diﬀerent wells under the ion transfer
capillary. A pulsed high voltage (HV, from 0 V to 8 kV,
frequency 20 Hz) was generated by amplifying voltage square
wave pulses (0 to 8 V) with a high voltage ampliﬁer
(10HVA24-P1, HVP High Voltage Products GmbH, Mar-
tinsried/Planegg, Germany), and applied on the electrode to
induce ESTASI against the ion transfer capillary that was set at
275 °C and always grounded. The ESI voltage of the internal
power of the MS instrument was always set as 0, and all the
source gas ﬂow rates were set at 0. An enhanced ion trap
scanning rate of 10,000 m/z per second was used. The other
parameters of the MS instrument were optimized for the
Figure 1. Schematic representation of the setup used for ESTASI-MS
from a 384-well plate. HV: high voltage, which is a square wave pulsed
HV here.
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selected analytes and not described here. All MS analyses were
performed under positive scanning mode. For the collision-
induced dissociation (CID), full scan mode was performed with
a normalized collision energy of 30 and isolation width of 1 m/
z.
Direct Infusion ESI. For sensitivity comparison, samples
were also analyzed via a direct infusion mode ESI with a syringe
at the ﬂow rate of 3 μL/min. The ESI was performed with the
commercially equipped ESI source of LTQ velos with a spray
emitter of 500 μm in diameter and assisted by a sheath gas ﬂow
of 10 arbitrary units and auxiliary gas ﬂow of 5 arbitrary units.
The ESI voltage was 3.7 kV. The temperatures of the heater
and the MS inlet capillary were set at 42 and 275 °C,
respectively. All other parameters of the MS instrument were
the same as those for ESTASI analysis.
■ RESULTS AND DISCUSSION
384-Well Plate ESTASI-MS. According to the previous
studies, ESTASI occurs during electrostatic charging/discharg-
ing of the capacitors formed by (i) an electrode−insulator−
electrolyte solution and (ii) an electrolyte solution−gas−ion
transfer capillary.20 Charge separation happens inside the
electrolyte solution during charging of the capacitors, e.g.
anions to the part close to the electrode and cations to the part
close to the ion transfer capillary when a positive HV is applied
on the electrode. When the charge density on the part close to
the ion transfer capillary is large enough, electrospray of cations
occurs. Afterward, spray of anions can be induced by simply
grounding the electrode to make the electrolyte solution
neutral. According to this ionization principle, it is crucial to
reach a large charge density to start ESTASI that can be realized
either by increasing the charge amount accumulated on the part
of the electrolyte solution close to the ion transfer capillary or
by reducing the surface area of the region. The charge amount
can be increased by increasing the HV, increasing the surface
area of the electrode, decreasing the thickness of the insulator,
and decreasing the distance from the electrolyte solution to the
ion transfer capillary.20
ESTASI has been realized with various setups, e.g. microchip
ESTASI, gel strip ESTASI, and ESTASI MS imaging from an
insulating plate.21,22,24 When the solution is inside the wells of a
microtiter plate, its surface area exposed to the ion transfer
capillary is determined by the shape of the well. A typical 96-
well plate has normally quasi-cylindrical wells (about 8 mm Ø)
with the volume up to 1 mL each, resulting in a large area of
sample solution inside exposed to the ion transfer capillary
during ESTASI. Indeed, it is very diﬃcult to perform direct
ESTASI of samples from a normal 96-well plate. Herein, we
chose a commercially available 384-well plate with cone-shaped
wells that had the volume of 40 μL each with the diameter of 3
mm at the base of the cone. When 10 μL of sample solution
was ﬁlled in a well for ESTASI-MS analysis, the liquid exposed
to the ion transfer capillary was discal-shaped with a diameter
less than 2 mm. The ion transfer capillary probed into the well
and kept the distance of 1−2 mm from the sample to avoid
sucking the sample solution into the capillary by vacuum
(Supporting Information Video 1). As soon as the pulsed HV
was applied on the electrode, ESTASI happened to produce
ions for MS analysis. Without the pulsed HV, no signal was
observed by the mass spectrometer. During ESTASI, the
sample was consumed, resulting in enlarging the distance
between the ion transfer capillary and the sample solution. This
would decrease the charge amount on the liquid surface, and
ﬁnally stop ESTASI. Therefore, the 384-well plate should be
lifted up carefully during ESTASI until all the sample solution
in the well was exhausted. The consumption of 10 μL of sample
solution normally needed 30 s. The analysis of many wells was
performed with the help of an x, y, z translation system.
The 384-well plate ESTASI-MS was tested with diﬀerent
samples, including small organic molecules, peptides, and
proteins. A group of synthetic antibiotics derived from
quinolone nalidixic acid, including ciproﬂoxacin (CIP),
enroﬂoxacin (ENR), lomeﬂoxacin (LOM), and ﬂeroxacin
(FLE), were selected as examples of small organic drug
molecules. These antibiotics were introduced for the
therapeutic treatment of respiratory and urinary infections
since the mid-1990s.25 The extensive use of the antibiotics has
led to their accumulation in food, which has potential health
hazards for humans.26 Therefore, it is highly important to
develop analytical techniques for the detection of trace amounts
of the antibiotics. As shown in Figure 2(a), an intense peak of
the single protonated CIP was obtained from 1.5 μM CIP in
50% MeOH/49% H2O/1% acetic acid by the 384-well plate
ESTASI-MS. When the concentration of CIP was lowered to
15 nM, the peak was still clearly observed with the signal-to-
noise (S/N) ratio >10 (Figure 2(b) and Table 1). Detection of
other antibiotics was also performed. When 1.4 μM LOM, FLE,
and ENR were used, peaks for the single protonated antibiotics
were easily observed. When the concentration was lowered to
140 nM, the peaks could still be observed but with the S/N of
only 4, 2, and 3 for LOM, FLE, and ENR, respectively (Table 1
and Supporting Information (SI) Figures SI-1, SI-2, and SI-3).
The results were compared with standard direct infusion ESI-
MS analysis of the same samples by the same linear ion trap
mass spectrometer (Thermo, LTQ Velos). Similar LOD was
demonstrated under the optimized instrumental conditions
(Table 1).
Figure 2. Mass spectra obtained by the 384-well plate ESTASI-MS of
(a) 1.5 μM CIP, (b) 15 nM CIP, (c) 15 μM Ang I, (d) 15 nM Ang I,
(e) 10 μM Cyt c, and (f) 100 nM Cyt c. Solution: 50% MeOH/49%
H2O/1% acetic acid. CIP + H
+: singly protonated CIP; (Ang I)x+: Ang
I ion with x proton(s); XH+: Cyt c ion with x proton(s).
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Peptide (angiotensin I (Ang I), 1295 Da) was also tested by
the 384-well plate ESTASI-MS. As illustrated in Figure 2(c), a
mass spectrum similar to that from the standard direct infusion
ESI-MS was obtained from 15 μM Ang I in 50% MeOH/49%
H2O/1% acetic acid. The LOD of Ang I by the 384-well plate
ESTASI-MS was found to be about 15 nM, where a peak at m/
z 649 for the doubly protonated Ang I was observed with the
S/N of 5 (Figure 2(d)). In contrast, standard infusion mode
ESI-MS needs at least 50 nM of Ang I to generate a clear peak
(S/N = 10) of the peptide at m/z 433 for the triply protonated
ion (Table 1).
The analysis of proteins by the 384-well plate ESTASI-MS
was demonstrated using cytochrome c from horse heart (Cyt c,
12 kDa). When the concentration of Cyt c was high (10 μM in
50% MeOH/49% H2O/1% acetic acid), the obtained mass
spectrum showed the strongest peak at m/z 1546 for the
protein ions with 8 protons (Figure 2(e)). The LOD was found
at 100 nM of Cyt c, with the strongest peak (S/N = 10) at m/z
773 for the protein ions with 16 protons. Direct infusion mode
ESI-MS provides the LOD of Cyt c (70 nM), slightly better
than the 384-well plate ESTASI-MS, with also the strongest
peak (S/N = 10) at m/z 773 (Table 1).
As shown in Table 1, diﬀerent samples show diﬀerent LODs
with the 384-well plate ESTASI-MS. The technique shows the
lowest LODs for CIP and Ang I, which are relatively small in
size and have basic amino groups (pKa = 8.68 for CIP and 8 for
Ang I) for protonation. ENR and FLE have the pKa of 6.68 and
6.06, respectively, making the protonation rather diﬃcult and
hence leading to high LODs. Cyt c is big in size and can only be
observed by ion trap mass spectrometer when it is highly
charged. When a cone-shaped well of a 384-well plate works as
a spray emitter for ESTASI, the solution exposed to ion transfer
capillary is discal-shaped with a diameter of 1−2 mm. The
increased emitter size will lead to low surface charge density.
During the analysis of proteins, the charge number tended to
low numbers to generate ions with large mass-to-charge ratio
values, which were diﬃcult to be detected by the ion trap mass
spectrometer. In general, the method is as sensitive as standard
direct infusion ESI-MS in the analysis of small organic
molecules and peptides, but less sensitive against proteins.
However, diﬀerent from the standard ESI-MS, the 384-well
plate ESTASI-MS can provide higher throughput and lower
sample consumption in analysis. During 384-well plate
ESTASI-MS, the sample volume in each well is normally
from 2 to 10 μL. The ionization device is simply a disposable
microtiter plate, where washing procedures are not required
from one analysis to the next. The analysis time per well is only
a few seconds to generate a mass spectrum. In contrast, direct
infusion ESI-MS requires either a LC autoinjector or
continuous syringe injection. In both cases of direct infusion
ESI-MS, washing of the liquid delivery part is required after
each analysis, which is time-consuming, especially when the
analytes are strongly adsorbed by the tubing system.
Enzyme Inhibition Assay by 384-Well Plate ESTASI-
MS. One of the potential applications of the 384-well plate
ESTASI-MS is the enzyme assay study. MS has drawn
increasing interest in enzyme activity assays and enzyme
inhibition assays during the last years.6 Compared to
spectroscopy-based methods, the MS strategy does not need
expensive labeling reagents, and provides highly accurate
identiﬁcation to avoid false positive results. Both laser
desorption/ionization (LDI) and electrospray ionization
(ESI)-based MS techniques are used for enzyme assay
study.8,27 The former holds the advantage of high throughput,
but diﬃculty in quantiﬁcation. The later provides better
quantiﬁcation, but is limited by throughput. ESTASI was
demonstrated as a concentration-dependent ionization techni-
que, similar to ESI, suitable for quantiﬁcation.22 Therefore, the
384-well plate ESTASI-MS can hold both the advantages of
quantitative analysis, like ESI-MS, and high throughput, like
LDI-MS. By avoiding the washing procedure, the time to
analyze a sample is only seconds.
The quantitative capability of 384-well plate ESTASI-MS was
demonstrated by detecting tyrosine of diﬀerent concentrations.
The classical method of internal standard calibration was used
for tyrosine quantiﬁcation, where serine was chosen as the
internal standard. The high correlation coeﬃcient value (R2 =
0.992) obtained from the ﬁtted curve in Figure SI-4 of the SI
indicates the good linear response of the relative ion intensities
to the tyrosine concentrations within the range 2−50 mg/L,
demonstrating the concentration-dependent ionization per-
formance of the 384-well plate ESTASI-MS.
To demonstrate the application in an enzyme assay, we
performed the oxidation of tyrosine in the presence of
tyrosinase without and with inhibitors, followed by ESTASI-
MS analysis. Oxidation of tyrosine catalyzed by tyrosinase,
peroxidases, or haem-containing proteins can form DOPA, 5,6-
dihydroxyindole (5,6-DHI), and ﬁnally melanin,28 as show in
Scheme 1. It is also involved in browning reactions in damaged
fruits.29 A number of wells were prepared containing tyrosine
(0.05 mg/mL) and tyrosinase (0.02 mg/mL) in 2 mM PBS
(pH 7.4), and incubated at room temperature for various
periods before ESTASI-MS analysis. After 3 min of reaction, a
clear peak for single protonated 5,6-DHI at m/z 150 was
Table 1. Comparison of the Detection of Antibiotics Ang I
and Cyt c by 384-Well Plate ESTASI-MS and Standard
Direct Infusion ESI-MS
Compound Method m/z LOD S/N
CIP ESTASI-MS 332 15 nM >10
CIP ESI-MS 332 15 nM 3
LOM ESTASI-MS 352 140 nM 4
LOM ESI-MS 352 140 nM 4
FLE ESTASI-MS 370 140 nM 2
FLE ESI-MS 370 140 nM 3
ENR ESTASI-MS 360 140 nM 3
ENR ESI-MS 360 140 nM 5
Ang I ESTASI-MS 649a 15 nM 5
Ang I ESI-MS 433b 50 nM 10
Cyt c ESTASI-MS 773c 100 nM 10
Cyt c ESI-MS 773c 70 nM 10
aDoubly protonated angiotensin I. bTriply protonated angiotensin I.
cCyt c with 16 protons.
Scheme 1. Oxidation of Tyrosine Catalyzed by Tyrosinase
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observed in Figure 3(a), together with a peak for singly
protonated tyrosine at m/z 182. The other oxidation products
were hardly observed, indicating that they were quickly
consumed after formation to produce 5,6-DHI or hardly
ionized for MS analysis. During ESTASI-MS analysis, the buﬀer
was 2 mM PBS at pH 7.4. Prolonging the reaction time, the
tyrosine concentration continued to decrease slowly. After 20
min of reaction, only a very weak peak of tyrosine was obtained
in Figure 3(b), indicating that most of the reactant was
consumed. The reaction kinetics was analyzed based on the
classic Michaelis−Menten kinetic process30 and followed a
pseudo-ﬁrst-order reaction with the reaction rate constant of
0.069 min−1, indicating that the Michaelis constant KM is much
larger than the substrate (tyrosine) concentration (0.05 mg/
mL) in this case (Figure 3(c) and (d)).
The inhibition of tyrosinase-catalyzed tyrosine oxidation is an
important topic in food and cosmetic chemistry to avoid
hyperpigmentation in human skin and enzymatic browning in
fruits or fungi.
Recently developed inhibitors have been summarized in
several reviews.29,31,32 In this work, we used two inhibitors,
ascorbic acid and Cupferron, to illustrate the feasibility of
applying the 384-well plate ESTASI-MS in enzyme inhibition
assays. Ascorbic acid is an antioxidant, working as an inhibitor
of many enzymatic oxidative reactions. The enzyme inhibition
assay was performed by preparing a number of wells containing
ascorbic acid at diﬀerent concentrations (0.1 and 0.01 mg/mL)
with tyrosine (0.05 mg/mL) and tyrosinase (0.02 mg/mL) in 2
mM PBS, followed by ESTASI-MS analysis after diﬀerent times
of incubation. As shown in Figure 4(a), tyrosine oxidation was
eﬃciently inhibited by 0.01 mg/mL ascorbic acid within 20 min
of incubation, but the tyrosine concentration started to
decrease sharply when prolonging the incubation time and
was almost completely consumed after 40 min. It suggests that
ascorbic acid works as a competitive inhibitor, continuously
consumed during the enzymatic reaction. In contrast, with a
higher concentration of ascorbic acid (0.1 mg/mL), the
inhibition can last eﬀectively for at least 40 min (in Figure
4(b)). Therefore, a successful and continuous inhibition
requires the proper amount of ascorbic acid or the addition
of ascorbic acid round-the-clock.
Cupferron is a metal-chelating agent that can coordinate the
copper ion of mushroom tyrosinase to inhibit completely its
activity.33 Replacing ascorbic acid by Cupferron, the inhibition
was studied by 384-well plate ESTASI-MS. As a competitive
inhibitor, the concentration of Cupferron should be suﬃciently
higher than that of tyrosine for the eﬃcient inhibition of
tyrosinase (0.15 μM). Theoretically, at least 1 mM of
Cupferron is required for complete inhibition of tyrosinase in
the presence of 0.3 mM tyrosine through calculation of the half
maximal inhibitory concentration (IC50), in the SI. Herein, 2
mM Cupferron was applied to ensure maximum inhibition of
tyrosinase. As shown in Figure 4(c), no oxidation product was
observed after 10 min of reaction. With longer incubation time,
the oxidation was still not observed by ESTASI-MS, consistent
with the proposed inhibition mechanism that Cupferron
completely deactivates tyrosinase. The strong peak in Figure
4(c) at m/z 157 was from Cupferron, which was also observed
by standard direct infusion ESI-MS of pure Cupferron in 50%
MeOH/49% H2O/1% acetic acid (Figure SI-5).
Drug Metabolites Screening by the 384-Well Plate
ESTASI-MS. Another important application of the 384-well
plate is drug candidate screening. In-vitro studies of the drug
Figure 3. Mass spectra of the products of tyrosine (0.05 mg/mL)
oxidation catalyzed by tyrosinase (0.02 mg/mL) after (a) 3 min and
(b) 20 min of reaction. (c) Concentration variation of tyrosine during
the enzyme-catalytic oxidization within 40 min. (d) Reaction kinetics
of tyrosine oxidation. The reaction was performed in the wells of a
384-well plate followed with direct ESTASI-MS analysis in a buﬀer
condition of 2 mM PBS at pH 7.4. Error bars show standard deviation
(n = 3).
Figure 4. Tyrosinase inhibition assay with diﬀerent amounts of ascorbic acid as the inhibitor: (a) 0.01 mg/mL of ascorbic acid; (b) 0.1 mg/mL of
ascorbic acid. (c) Mass spectrum obtained after 10 min of reaction inhibited by 2 mM of Cupferron. The reactions were performed in 10 μL
solutions containing 0.05 mg/mL of tyrosine, 0.02 mg/mL of tyrosinase, and diﬀerent amounts of inhibitors in a buﬀer of 2 mM PBS at pH 7.4 in
the wells of a 384-well plate followed by direct ESTASI-MS analysis.
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candidate metabolism could predict its potential toxicity, which
is crucial in early stage drug discovery.34 The rapid develop-
ments of combinatorial chemistry and advances in bioinfor-
matics, genomics, and proteomics have driven the potential
targets for new drug development increase dramatically in the
past decade.35 Therefore, low cost, rapid and high throughput
drug candidate screening methods are urgently needed. 384-
well plate screening combined with ESTASI-MS or ESTASI-
MS/MS can be applied in drug candidate screening by
characterizing the metabolites of drug candidates in a high
throughput manner.
To demonstrate this application, cytochrome P450, one
major family of human liver microsome enzymes widely used
for in vitro metabolism and toxicity studies,36 was chosen to
induce drug metabolism in the wells of microtiter plates, while
nifedipine and testosterone were used as substrates. Nifedipine
is a prototype of the dihydropyridine class of calcium channel
blockers that is widely used in the treatment of hypertension,
prinzmtal’s angina pectoris, and other vascular disorders,37
while testosterone is a male sex hormone that is important for
sexual and reproductive development and plays a vital role in
carbohydrate, fat, and protein metabolism.38
The CYP3A4-catalyzed metabolisms of both nifedipine and
testosterone were simultaneously studied by 384-well plate
ESTASI-MS during a single run analysis. In both cases,
NADPH was added as an electron donor. Multiple wells in a
384-well plate were ﬁlled with 10 μL of solutions, each
containing 64 μg/mL of nifedipine or 32 μg/mL of
testosterone, 1 mg/mL of NADPH, and 0.1 μM CYP3A4 in
10 mM NH4HCO3 (pH 7.4). The solutions were incubated for
a certain time under room temperature and then directly
analyzed by ESTASI-MS at diﬀerent time intervals. The
tolerance to a salty solution of the 384-well plate ESTASI-
MS was estimated be around 30 mM NaCl for the analysis of
50 nM Ang I, as shown in Figure SI-6. Considering that the
high concentration of salts (around 30 mM) in the reaction
solution could hinder the eﬃcient detection of the drugs and
their metabolic products, 9 μL of the reaction mixture was
discarded and replaced by 9 μL of the ionization buﬀer (50%
MeOH/49% H2O/1% acetic acid) for ESTASI-MS analysis.
The primary product of nifedipine metabolism catalyzed by
CYP3A4 is dehydronifedipine with the m/z at 345, as shown in
Scheme 2(a) and Figure 5(d), which is consistent with the
literature report.37 After 30 min of incubation, the majority of
nifedipine was oxidized, and the conversion ratio reached
around 70%, as shown in Figure 5(a). When prolonging the
reaction time to 90 min, little nifedipine was further oxidized. A
linear regression was obtained in Figure 5(b) and the nifedipine
oxidation could be considered as the pseudo-ﬁrst-order
reaction. Within 30 min, the reaction rate constant was
determined as 0.037 min−1, in Figure 5(b).
Structural elucidation of drug candidate metabolic products
could facilitate the prediction of its toxicity based on the
regression model of quantitative structure−toxicity relationship
(QSTR), which relates the structure variables to the potency of
toxicity variables.39 For this purpose, tandem MS with collision-
induced dissociation (CID) was further applied to characterize
the structure of the oxidized nifedipine. With normalized
collision energy of 30, the precursor ion of m/z 345 generated a
predominant fragment ion with m/z 284, corresponding to the
loss of CH3COOH from the metabolic product, in Figure 5(e).
Both the precursor ion and the fragments indicated the
generation of dehydronifedipine.
Metabolic oxidation of testosterone was also monitored in
the same 384-well plate together with nifedipine during a single
run of analysis. From Scheme 2(b) and Figure 6(d), the
testosterone metabolism generated hydroxytestosterone and
6β-hydroxytestosterone is the primary structure, according to
the literature report.38 Figure 6(a) and (b) presented the
oxidation process and only 40% of conversion ratio was
obtained until 90 min of incubation. A reaction rate constant
was obtained as 0.0072 min−1 for the metabolism of
testosterone (Figure 6(b)). The corresponding mass spectra
of the testosterone and its oxidation product are shown in
Figure 6(c) and (d). The metabolic product ion with m/z 305
was selected for the CID process and generated the primary
fragments by the detachment of two −OH groups, conﬁrming
the formation of hydroxytestosterone (Figure 6(e)).
These results show that the 384-well plate ESTASI-MS/MS
provides the possibility to directly characterize metabolic
products in a high speed and throughput way without any
solution puriﬁcation or delivery interface. The 384-well plate
ESTASI-MS and ESTASI MS/MS will be of great value in rapid
and accurate in vitro drug metabolism study and toxicity
prediction.
■ CONCLUSION
In conclusion, we have realized direct ionization of liquid
samples inside a microtiter plate by electrostatic spray
ionization. Analytical characteristics, including sensitivity and
quantiﬁcation capability, were evaluated. The method can be
universally applied for a wide range of samples, from organic
molecules with molecular weights of ∼150 Da to proteins of
>10 kDa. The ionization device is demonstrated as eﬃcient as
standard ESI in view of sensitivity to trace amount of analytes,
while it also holds advantages in analysis throughput. Two
applications were further explored: enzyme assay and drug
metabolism screening. We would expect the current ionization
method to be a powerful tool in high throughput MS-based
enzyme activity assays, enzyme inhibition assays, immuno-
assays, and drug candidate screenings.
Scheme 2. Oxidative Metabolism of (a) Nifedipine and (b)
Testosterone Catalyzed by Cytochrome P450 CYP3A4
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Figure 5. Fitted curves and mass spectra for CYP3A4-catalyzed metabolism of nifedipine. (a) Conversion ratio of nifedipine as a function of time.
(b) Reaction kinetics of nifedipine metabolism. (c and d) Mass spectra of nifedipine and its metabolites before reaction and after 30 min of reaction,
respectively. (e) CID spectrum of the precursor ion at m/z 345 with normalized collision energy of 30 and isolation width of 1 m/z. The reactions
were performed with 64 μg/mL of nifedipine, 1 mg/mL of NADPH, and 0.1 μM of CYP3A4 in 10 μL of 10 mM NH4HCO3 (pH 7.4) in a 384-well
plate. Nine μL of the reaction solution was discarded and replaced with 9 μL of the ionization buﬀer (50% MeOH/49% H2O/1% acetic acid) prior
to ESTASI-MS analysis.
Figure 6. Fitted curves and mass spectra for the CYP3A4-catalyzed metabolism of testosterone. (a) Conversion ratio of testosterone as a function of
time. (b) Reaction kinetics of testosterone metabolism. (c and d) Mass spectra of testosterone and its metabolites before reaction and after 90 min
reaction, respectively. (e) CID spectrum of the precursor ion at m/z 305 with normalized collision energy of 30 and isolation width of 1 m/z. The
reactions were performed with 32 μg/mL of nifedipine, 1 mg/mL of NADPH, and 0.1 μM of CYP3A4 in 10 μL of 10 mM NH4HCO3 (pH 7.4) in a
384-well plate. Nine μL of the reaction solution was discarded, replaced with 9 μL of the ionization buﬀer (50% MeOH/49% H2O/1% acetic acid)
prior to ESTASI-MS analysis.
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